Acquisition

RNS Number:3030W
Goldshield Group PLC
22 December 2000


FOR IMMEDIATE RELEASE:

22 December 2000



                             Goldshield Group PLC



   Acquisition of the Traxam Range from American Home Products Corporation


Goldshield Group PLC (the "Company") today announces the acquisition of
licenses, trademarks and know-how (the "Rights") of the Traxam range of
products for the UK and the Republic of Ireland from American Home Products
Corporation ("AHPC").

The Traxam range relates to those products containing felbinac - a
non-steroidal anti-inflammatory drug.  The full AHPC range consists of the
prescription product, Traxam, and the over the counter product, Traxam Pain
Relief Gel.  Both are topical, anti-inflammatory and analgesic products given
for the relief of symptoms associated with soft tissue injuries, rheumatic
pain and non-serious arthritic conditions.  The Traxam gel formulated is
subject to patent protection in the UK until the year 2004 and in respect of
the foam presentation it is patent protected in the UK and Republic of Ireland
until 2010.  AHPC currently sells Traxam in the UK and Republic of Ireland
with Traxam Pain Relief Gel having only, to date, been sold within the UK.

Rights to the Traxam range have been acquired by Goldshield for a cash
consideration of #4.0 million.  This settlement is due in phased payments with
#2.0 million payable on completion, #1.0 million payable in March 2001 and #
1.0 million payable in June 2001. In addition, the Company has agreed to
acquire stocks of finished products not exceeding six months sales.

Net sales for the countries in which Rights are being acquired for the year to
30 November 2000 were #3.9 million. Operating under AHPC's charging structure
and cost base the profit for the same period to 30 November 2000 was #0.8
million with sales on prescription in the UK, at trade prices, being #3.99
million (source: BPI 10/00).



Ajit Patel, Executive Chairman of Goldshield Group PLC, said:



"The Traxam range fits our acquisition criteria perfectly being an already
strong brand in a sizeable but expandable market. We believe that Goldshield
can expand sales within the UK for both of the Traxam products and we hope to
discover an active market in Traxam Pain Relief Gel in the Republic of Ireland
- a new market for this product."

                                   - ENDS -



                                    - 2 -





For Further Information Please Contact:


Goldshield Group PLC                 Tel: [phone]

Ajit Patel, Executive Chairman

Rakesh Patel, Finance Director



Buchanan Communications               Tel: [phone]

Louise Bolton



Notes to editors:

Goldshield Group PLC a profitable, British, marketing-led, emerging
pharmaceutical company based in Croydon, Surrey, was founded in 1990, to sell
healthcare and pharmaceutical products internationally.  In June 1998 the
Group floated on the London Stock Exchange and currently has a market
capitalisation of approximately #280 million.